Vienna, 07.02.2023. With its new, broad-based management, AOP Health is responding to changes in the pharmaceutical industry: the pandemic and the associated supply bottlenecks, issues with the supply chain and logistics, as well as the global economic challenges and the associated inflation, are placing complex demands on the industry.
Martin Steinhart and Bernhard Nachbaur, the two new CEOs of AOP Orphan Pharmaceuticals GmbH have been working in upper management at AOP Health for several years, and know both the industry and the company well from different perspectives.
Core task research and development
Martin Steinhart is a medical doctor and has worked in the pharmaceutical industry for more than 20 years in local, regional, and global roles. Steinhart, who is known for his entrepreneurial skills and business savvy, will, among other things, be responsible for research and development, medical affairs, business development, technical operations and the program management office as Co-CEO of AOP Orphan Pharmaceuticals GmbH.